A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types

Uloženo v:
Podrobná bibliografie
Vydáno v:Nature Communications vol. 16, no. 1 (2025), p. 1070
Vydáno:
Nature Publishing Group
Témata:
On-line přístup:Citation/Abstract
Full Text - PDF
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

MARC

LEADER 00000nab a2200000uu 4500
001 3163047421
003 UK-CbPIL
022 |a 2041-1723 
024 7 |a 10.1038/s41467-024-55059-3  |2 doi 
035 |a 3163047421 
045 2 |b d20250101  |b d20251231 
084 |a 145839  |2 nlm 
245 1 |a A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types 
260 |b Nature Publishing Group  |c 2025 
513 |a Journal Article 
520 3 |a Identifying tumor-specific T cell clones that mediate immunotherapy responses remains challenging. Mutation-associated neoantigen (MANA) -specific CD8+ tumor-infiltrating lymphocytes (TIL) have been shown to express high levels of CXCL13 and CD39 (ENTPD1), and low IL-7 receptor (IL7R) levels in many cancer types, but their collective relevance to T cell functionality has not been established. Here we present an integrative tool to identify MANA-specific TIL using weighted expression levels of these three genes in lung cancer and melanoma single-cell RNAseq datasets. Our three-gene “MANAscore” algorithm outperforms other RNAseq-based algorithms in identifying validated neoantigen-specific CD8+ clones, and accurately identifies TILs that recognize other classes of tumor antigens, including cancer testis antigens, endogenous retroviruses and viral oncogenes. Most of these TIL are characterized by a tissue resident memory gene expression program. Putative tumor-reactive cells (pTRC) identified via MANAscore in anti-PD-1-treated lung tumors had higher expression of checkpoint and cytotoxicity-related genes relative to putative non-tumor-reactive cells. pTRC in pathologically responding tumors showed distinguished gene expression patterns and trajectories. Collectively, we show that MANAscore is a robust tool that can greatly enrich candidate tumor-specific T cells and be used to understand the functional programming of tumor-reactive TIL.Although individual genes that distinguish tumor-reactive CD8+ T cells from bystander T cells in tumors have been described, a functionally meaningful integrative signature has not been established. Here authors show that mutation-associated neoantigen-specific CD8+ tumor-infiltrating lymphocytes can be recognized by MANAscore, an algorithm that uses weighted expression levels of CXCL13, ENTPD1 and IL7R in single-cell RNAseq datasets of lung cancer and melanoma patients as input. 
653 |a Cytotoxicity 
653 |a Endogenous retroviruses 
653 |a Tumors 
653 |a Algorithms 
653 |a Immunotherapy 
653 |a Genes 
653 |a Lymphocytes T 
653 |a Lung cancer 
653 |a Neoantigens 
653 |a Mutation 
653 |a CXCL13 protein 
653 |a Antigen (tumor-associated) 
653 |a Antigens 
653 |a Melanoma 
653 |a Immunological memory 
653 |a Lymphocytes 
653 |a Datasets 
653 |a Interleukin 7 receptors 
653 |a Gene expression 
653 |a Functional programming 
653 |a Cloning 
653 |a Tumor-infiltrating lymphocytes 
653 |a PD-1 protein 
653 |a CD8 antigen 
653 |a Environmental 
773 0 |t Nature Communications  |g vol. 16, no. 1 (2025), p. 1070 
786 0 |d ProQuest  |t Health & Medical Collection 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3163047421/abstract/embedded/L8HZQI7Z43R0LA5T?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3163047421/fulltextPDF/embedded/L8HZQI7Z43R0LA5T?source=fedsrch